high risk diffuse large B-cell lymphoma
Conditions
Brief summary
Disease free survival measured from the date of registration to relapse or death from any cause whichever comes first.
Detailed description
(Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire., Overall survival, calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive., The relationship between MRD status at the end-of-induction and endof- consolidation therapy., The relation between MRD conversion and 2-years DFS and OS., The relationship between T-cell repertoire, PDL1/HLA expression, mutational load, gene immune signature, microbiome and effect of atezolizumab on MRD conversion., The relation between the T-cell and NK cell repertoire and adverse events.
Interventions
Sponsors
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival measured from the date of registration to relapse or death from any cause whichever comes first. | — |
Secondary
| Measure | Time frame |
|---|---|
| (Severe) Adverse Events and the relation of adverse events in time to the recovery of the T-cell repertoire., Overall survival, calculated from registration until death from any cause. Patients still alive or lost to follow up are censored at the last date known to be alive., The relationship between MRD status at the end-of-induction and endof- consolidation therapy., The relation between MRD conversion and 2-years DFS and OS., The relationship between T-cell repertoire, PDL1/HLA expression, mutational load, gene immune signature, microbiome and effect of atezolizumab on MRD conversion., The relation between the T-cell and NK cell repertoire and adverse events. | — |
Countries
Belgium, Netherlands
Outcome results
None listed